Jack Allen
Stock Analyst at Baird
(0.96)
# 3,728
Out of 4,883 analysts
42
Total ratings
37.5%
Success rate
-11.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Maintains: Neutral | $0.25 → $1 | $2.67 | -62.55% | 4 | Jun 27, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.06 | +277.36% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.16 | +675.86% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.40 | +153.16% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $7.40 | +440.54% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $65.58 | +61.63% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $10.25 | +75.61% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $23.64 | +661.42% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.92 | +173.97% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $51.19 | +1.58% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $32.41 | +159.18% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.34 | +241.88% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.95 | +426.09% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.58 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.04 | +196.05% | 1 | Oct 7, 2021 | |
Vor Biopharma
Jun 27, 2025
Maintains: Neutral
Price Target: $0.25 → $1
Current: $2.67
Upside: -62.55%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.06
Upside: +277.36%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.16
Upside: +675.86%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.40
Upside: +153.16%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $7.40
Upside: +440.54%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $65.58
Upside: +61.63%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $10.25
Upside: +75.61%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $23.64
Upside: +661.42%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.92
Upside: +173.97%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $51.19
Upside: +1.58%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $32.41
Upside: +159.18%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.34
Upside: +241.88%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.95
Upside: +426.09%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.58
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.04
Upside: +196.05%